Compare S&P500 ETF (SPY) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
S&P500 ETF vs Tilray Brands Inc — how do they compare? S&P500 ETF trades at $776.26 (market cap $821.54B), while Tilray Brands Inc trades at $3.5 (market cap $530.54M). The key difference: S&P500 ETF is far larger — about 1548.5× Tilray Brands Inc's market cap, and S&P500 ETF is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold S&P500 ETF for 205 Days and Tilray Brands Inc for 31 Days on average.
| SPY | TLRY | |
|---|---|---|
Market Cap | $821.54B | $530.54M |
Volume | 40,070,358 | 9,099,075 |
52-Week High | $779.14 | $21.00 |
52-Week Low | $631.99 | $3.57 |
Typical Hold Time | 205 Days | 31 Days |
Sector | — | Health |
Enterprise Value | — | $684.46M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPY, the SPDR S&P 500 ETF, trades at $777.26, down 0.24% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The ETF is near its pivot point of $776, with immediate resistance at $779. Recent news highlights mixed sentiment, with some articles pointing to strong corporate earnings growth in 2026 but expected deceleration in 2027, while others discuss defensive positioning and valuation concerns.
The outlook for SPY is cautiously optimistic, supported by bullish technical trends and robust earnings growth projections for 2026. Key risks include potential profit growth slowdown in 2027, elevated market valuations, and macroeconomic headwinds such as rising Treasury yields. Investors should weigh the ETF's broad market exposure against these factors for long-term positioning.
TLRY trades at $3.715, down 1.72% on the day and near its 52-week low, reflecting persistent bearish technical momentum. The company reported revenue of $821.31M in 2025 but a substantial net loss of -$2.19B, with negative cash flow from operations. Recent quarters show consistent earnings misses versus expectations, though analyst consensus suggests a high price target of $65.01 amid mixed sentiment.
The outlook remains challenged by profitability issues and high debt, but potential catalysts include U.S. cannabis regulatory changes. Investment opportunities hinge on speculative regulatory shifts, while risks include ongoing losses, competitive pressures, and reliance on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
